Moureau-Zabotto Laurence, Teissier Eric, Cowen Didier, Azria David, Ellis Steve, Resbeut Michel
Department of Radiation Therapy, Institut Paoli Calmettes, 232 boulevard de Sainte Marguerite, 13009 Marseille, France.
Azurean Cancer Center, Mougins, France.
Gastroenterol Res Pract. 2015;2015:404203. doi: 10.1155/2015/404203. Epub 2015 Sep 10.
The aim of the study is to analyze the impact of the Siewert classification on the pathological complete response (pcR), pattern of failure, and general outcome of patients treated, by preoperative chemoradiotherapy and surgery for an gastroesophageal junction adenocarcinoma (OGJA). From 2000 to 2008, the charts of 68 patients were retrospectively reviewed. Tumor staging reported was UST1/T2/T3/T4/unknown, respectively, n = 1/7/54/5/1 patients, and N0/N1/unknown, respectively, n = 9/58/1 patients. Patients received primary external-beam radiotherapy with concurrent chemotherapy followed by surgical resection (Siewert I: upper oesogastrectomy; Siewert II/III: total gastrectomy with lower oesophagectomy). Overall survival (OS), overall relapse rate (ORR), cumulative rate of local (CRLR), nodal (CRNR), and metastatic (CRMR) relapse, and their prognostic factors were retrospectively analyzed. Median follow-up was 77.5 months. Median OS was 41.7 ± 5.2 months. The 3-year ORR was 48%. Using univariate analysis ORR was significantly increased for patients with Siewert II/III compared to Siewert I tumors (27.3% versus 62%, p = 0.047). Siewert I tumors had also statistically lower CRNR and CRMR compared to Siewert II/III tumors (0/9.1% versus 41.3/60.2% resp., p = 0.012), despite an equivalent cumulative rate of local relapse and pathological complete response rate between the three groups. For OGJA treated with preoperative CRT and surgery, ORR and CRMR were lower for patients with Siewert I tumors in comparison with Siewert II/III tumors.
本研究旨在分析Siewert分型对接受术前放化疗及手术治疗的胃食管交界腺癌(OGJA)患者的病理完全缓解(pcR)、失败模式及总体预后的影响。回顾性分析了2000年至2008年68例患者的病历。报告的肿瘤分期分别为UST1/T2/T3/T4/未知,n = 1/7/54/5/1例患者,N0/N1/未知,分别为n = 9/58/1例患者。患者接受了外照射放疗联合同步化疗,随后进行手术切除(Siewert I型:上食管胃切除术;Siewert II/III型:全胃切除术加下食管切除术)。对总生存期(OS)、总复发率(ORR)、局部(CRLR)、淋巴结(CRNR)和远处转移(CRMR)复发的累积率及其预后因素进行了回顾性分析。中位随访时间为77.5个月。中位OS为41.7±5.2个月。3年ORR为48%。单因素分析显示,与Siewert I型肿瘤患者相比,Siewert II/III型肿瘤患者的ORR显著升高(27.3%对62%,p = 0.047)。与Siewert II/III型肿瘤相比,Siewert I型肿瘤的CRNR和CRMR在统计学上也较低(分别为0/9.1%对41.3/60.2%,p = 0.012),尽管三组之间局部复发累积率和病理完全缓解率相当。对于接受术前放化疗及手术治疗的OGJA患者,与Siewert II/III型肿瘤患者相比,Siewert I型肿瘤患者的ORR和CRMR较低。